Session

Big steps for coeliac and short bowel

TERIFLUNOMIDE AS IMMUNOTHERAPY FOR CELIAC DISEASE – RESULTS FROM A DOUBLE-BLINDED, RANDOMIZED PHASE 2A STUDY
TERIFLUNOMIDE AS IMMUNOTHERAPY FOR CELIAC DISEASE – RESULTS FROM A DOUBLE-BLINDED, RANDOMIZED PHASE 2A STUDY

Big steps for coeliac and short bowel  et al.

SEROLOGICAL SIGNS OF COELIAC DISEASE IN PRE-DIAGNOSTIC SAMPLES FROM A POPULATION-BASED COHORT OF COELIACS, THE TRØNDELAG HEALTH STUDY (HUNT), NORWAY
SEROLOGICAL SIGNS OF COELIAC DISEASE IN PRE-DIAGNOSTIC SAMPLES FROM A POPULATION-BASED COHORT OF COELIACS, THE TRØNDELAG HEALTH STUDY (HUNT), NORWAY

Big steps for coeliac and short bowel  et al.

PHARMACODYNAMIC DEMONSTRATION OF IMMUNOLOGICAL TOLERANCE INDUCED BY KAN-101, A NOVEL LIVER-TARGETED THERAPY FOR COELIAC DISEASE, PERSISTS FOLLOWING DRUG CLEARANCE
PHARMACODYNAMIC DEMONSTRATION OF IMMUNOLOGICAL TOLERANCE INDUCED BY KAN-101, A NOVEL LIVER-TARGETED THERAPY FOR COELIAC DISEASE, PERSISTS FOLLOWING DRUG CLEARANCE

Big steps for coeliac and short bowel  et al.

EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL
EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL

Big steps for coeliac and short bowel  et al.

EVALUATION OF SOMATIC MUTATIONS IDENTIFIED IN SMALL INTESTINAL MUCOSA USING A GENE PANEL IN PATIENTS WITH SMALL INTESTINAL MALABSORPTIVE ENTEROPATHIES
EVALUATION OF SOMATIC MUTATIONS IDENTIFIED IN SMALL INTESTINAL MUCOSA USING A GENE PANEL IN PATIENTS WITH SMALL INTESTINAL MALABSORPTIVE ENTEROPATHIES

Big steps for coeliac and short bowel  et al.

TERIFLUNOMIDE AS IMMUNOTHERAPY FOR CELIAC DISEASE – RESULTS FROM A DOUBLE-BLINDED, RANDOMIZED PHASE 2A STUDY
TERIFLUNOMIDE AS IMMUNOTHERAPY FOR CELIAC DISEASE – RESULTS FROM A DOUBLE-BLINDED, RANDOMIZED PHASE 2A STUDY

EVALUATION OF SOMATIC MUTATIONS IDENTIFIED IN SMALL INTESTINAL MUCOSA USING A GENE PANEL IN PATIENTS WITH SMALL INTESTINAL MALABSORPTIVE ENTEROPATHIES
EVALUATION OF SOMATIC MUTATIONS IDENTIFIED IN SMALL INTESTINAL MUCOSA USING A GENE PANEL IN PATIENTS WITH SMALL INTESTINAL MALABSORPTIVE ENTEROPATHIES

PHARMACODYNAMIC DEMONSTRATION OF IMMUNOLOGICAL TOLERANCE INDUCED BY KAN-101, A NOVEL LIVER-TARGETED THERAPY FOR COELIAC DISEASE, PERSISTS FOLLOWING DRUG CLEARANCE
PHARMACODYNAMIC DEMONSTRATION OF IMMUNOLOGICAL TOLERANCE INDUCED BY KAN-101, A NOVEL LIVER-TARGETED THERAPY FOR COELIAC DISEASE, PERSISTS FOLLOWING DRUG CLEARANCE

SEROLOGICAL SIGNS OF COELIAC DISEASE IN PRE-DIAGNOSTIC SAMPLES FROM A POPULATION-BASED COHORT OF COELIACS, THE TRØNDELAG HEALTH STUDY (HUNT), NORWAY
SEROLOGICAL SIGNS OF COELIAC DISEASE IN PRE-DIAGNOSTIC SAMPLES FROM A POPULATION-BASED COHORT OF COELIACS, THE TRØNDELAG HEALTH STUDY (HUNT), NORWAY

EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL
EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL

Item 1 - 10 / 10
1